Unveiling the Sweet Secret: Sugar's Role in Bacterial Defense
Scientists in Australia have made a groundbreaking discovery that could revolutionize the fight against drug-resistant bacteria. They've found a hidden weakness in some of the world's most dangerous pathogens: a sugar molecule unique to bacterial cells. This sugar, known as pseudaminic acid, is a key player in the bacteria's ability to evade the immune system, making it an ideal target for new treatments.
The research, published in Nature Chemical Biology, showcases how antibodies can be engineered to recognize and target this sugar molecule. By creating these antibodies in the lab, scientists have developed a potential new class of therapies that can combat infections resistant to even the strongest antibiotics. In lab tests, these antibodies successfully cleared lethal infections in mice by homing in on the sugar and marking the bacteria for destruction by the immune system.
Led by Professor Richard Payne at the University of Sydney, the team also included Professor Ethan Goddard-Borger from WEHI and Associate Professor Nichollas Scott from the University of Melbourne and the Peter Doherty Institute for Infection and Immunity. Professor Payne highlights the interdisciplinary nature of the research, stating, 'This work showcases the power of combining chemistry, immunology, and microbiology. By synthesizing the bacterial sugar in the lab, we could map its shape and develop antibodies that latch on with precision, opening the door to treatments for some of the most stubborn infections in modern healthcare.'
The target sugar, pseudaminic acid, is found only in bacteria and is essential for many pathogens to evade immune responses. Since humans do not produce it, this sugar is an ideal target for selective therapy. The team used synthetic chemistry to build sugar-decorated molecules to understand the sugar's position on bacterial surfaces and created a 'pan-specific' antibody that recognizes the sugar across multiple bacterial species.
In preclinical models, the antibody successfully eliminated multidrug-resistant Acinetobacter baumannii, a leading cause of hospital-acquired pneumonia and bloodstream infections. Professor Goddard-Borger emphasizes the potential of this approach, saying, 'Some of these bacteria resist nearly all available antibiotics. Our approach provides a proof-of-concept that passive immunotherapy can take the fight to these pathogens.'
Beyond treatment, the antibodies also serve as tools to map bacterial virulence, allowing researchers to see where these sugars appear and how they change across strains. This information directly contributes to better diagnostics and therapies. Over the next five years, the team aims to advance these antibodies into clinical-ready therapeutics, potentially neutralizing one of the most notorious pathogens in the ESKAPE group of multidrug-resistant bacteria.
Professor Payne concludes, 'This is exactly the type of discovery our new ARC Centre of Excellence was designed to enable - turning molecular insights into real-world solutions that protect the most vulnerable patients.' For more information, visit [https://ilmt.co/PL/qBd4].
